Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 8/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | STS | P08842 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.44 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6579608 | 0.89 | HSD17B3 (0.65) | HSD17B3L3MBTL1ALDH1A1STSHTR7 | |
| SCHEMBL3027932 | 0.87 | HSD17B3 (0.66) | HSD17B3L3MBTL1ALDH1A1STSHTR7 | |
| SCHEMBL8576829 | 0.86 | HSD17B3 (0.64) | HSD17B3L3MBTL1HPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL6839650 | 0.85 | HSD17B3 (0.67) | HSD17B3L3MBTL1STSHTR7 | |
| SCHEMBL3844202 | 0.85 | HSD17B3 (0.67) | HSD17B3L3MBTL1STSHTR7 | |
| SCHEMBL9506499 | 0.85 | HSD17B3 (0.67) | HSD17B3L3MBTL1STSHTR7 | |
| SCHEMBL26254861 | 0.85 | HSD17B3 (0.82) | HSD17B3L3MBTL1HPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL6577194 | 0.83 | ALDH1A1 (0.56) | HSD17B3L3MBTL1HPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL4904631 | 0.82 | HSD17B3 (0.60) | HSD17B3L3MBTL1HPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL8533739 | 0.82 | ALDH1A1 (0.50) | HSD17B3L3MBTL1HPGDSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101844972-B | Improved method for preparing aromatic ketone | CHANGZHOU INST ENG TECH | 2013-04-24 | — | — | CN | disclosed |
| CN-101844972-A | Improved method for preparing aromatic ketone | CHANGZHOU INST ENG TECH | 2010-09-29 | — | — | CN | disclosed |
| EP-0856007-B1 | CYCLOPEPTIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2004-04-21 | — | — | EP | disclosed |
| US-6566491-B2 | Used as integrin inhibitors, in particular for the prevention and treatment of circulatory diseases, thrombosis, heart infarct, coronary heart diseases, arteriosclerosis, angiogenic diseases and in tumor therapy. | MERCK PATENT GESELLSCHAFT (DE) | 2003-05-20 | — | — | US | disclosed |
| US-20020032306-A1 | CYCLOPEPTIDE DERIVATIVES | BIOMET DEUTSCHLAND GMBH (DE) | 2002-03-14 | — | — | US | disclosed |
| US-4018507-A | Liquid crystal device, composition therefor, and method for preparing the composition | AMERICAN MICRO-SYSTEMS, INC. (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032306-A1 | CYCLOPEPTIDE DERIVATIVES | CORO1C, CYCS, CORO1A | HSD17B3 943/4885L3MBTL1 2192/4885HPGD 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.